The Trump administration is reportedly close to announcing a major deal with drugmakers Eli Lilly and Novo Nordisk to significantly lower the cost of their GLP-1 weight loss drugs — Zepbound and Wegovy — in exchange for limited Medicare coverage.
The deal could reduce drug prices to as low as $149/month for the lowest doses — a dramatic drop from the current list prices of over $1,000 per month. In return, Medicare may cover the drugs for some beneficiaries, though details remain murky.
The George Washington University has experts available to comment on lowering the cost of prescription drugs. If you are interested in scheduling an interview with a GW expert please contact Katelyn Deckelbaum, katelyn [dot] deckelbaum
gwu [dot] edu (katelyn[dot]deckelbaum[at]gwu[dot]edu).
Leighton Ku, a professor of health policy and management and Director of the Center for Health Policy Research at the GW Milken Institute School of Public Health, is a health policy researcher and public policy analyst. He is an expert in national and state health reforms.
Richard Ricciardi is associate dean for Clinical Practice and Community Engagement in the GW School of Nursing and the executive director for the Center for Health Policy and Media Engagement.
Tony Yang, is a professor in health policy at the George Washington University School of Nursing with a joint appointment at the Milken Institute School of Public Health in the Department of Health Policy and Management.
-GW-